nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial
Peter Oppelt(Washington University in St. Louis), Douglas R. Adkins(Washington University in St. Louis), Ryan S. Jackson(Washington University in St. Louis), Jason T. Rich(Washington University in St. Louis), Jingxia Liu(Washington University in St. Louis), Mark M. Gitau(Sanford Health), William C. Spanos(Sanford Health), Patrik Pipkorn(Washington University in St. Louis), José P. Zevallos(University of Pittsburgh Medical Center), Mackenzie Daly(University of Colorado Colorado Springs), Randal C. Paniello, Wade L. Thorstad(Washington University in St. Louis), Steven Powell(Georgetown University), Hiram A. Gay(Washington University in St. Louis), Kevin Palka(Washington University in St. Louis), Prakash Neupane(University of Kansas Medical Center), Jessica Ley(Washington University in St. Louis)
Cited by 18
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial
|The Lancet Oncology|2013|748
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
|Journal of Clinical Oncology|2017|653
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018
|Journal of the National Comprehensive Cancer Network|2018|632